Press: LPA and URMC Team to Tackle Parkinson's
Posted: Aug 12, 2014 | Author: Matt CorridoniCategory: Healthcare | Tags:
LPA Software Solutions’ Predictive Analytics team has announced a joint effort with the Center for Human Experimental Therapeutics (CHET) of the University of Rochester Medical Center to better understand the disease course of Parkinson’s disease.
There are no proven therapies that can delay, stop, or reverse the clinical or neuropathological progression of Parkinson’s disease. This is primarily because Parkinson’s disease is slow and heterogeneous in symptomatic progression, and there is an absence of biomarkers, making it difficult to fully assess treatment effects on outcome measures. However, patient characteristics such as age of disease onset and presentation of initial symptoms (tremor- vs. non-tremor-dominant) partially explain variability in disease course, suggesting the possibility of targeting subpopulations of PD patients with similar and more responsive clinical phenotypes.